[ad_1]
OXFORD, England, April 15, 2019 / PRNewswire / – Enesi Pharma ("Enesi"), an innovative pharmaceutical company developing unique injectable vaccine products based on drugs, has announced the conclusion of a public-private partnership with DRIVe of the US Department of Health. Biomedical Research and Development (BARDA) (Division of Research, Innovation and Enterprise) to develop new influenza vaccines using Enesi's ImplaVax® formulation and device technology.
ImplaVax® is a new formulation technology and needle-free device that allows solid dose vaccine implants to be put up quickly under the skin. The goal of this technology is that health care providers or the people themselves administer the vaccine using this simple, convenient and reusable device without needles. ImplaVax® can also generate an improved immune response, as well as reduced storage and distribution costs.
This new program aims to provide cost-effective technological innovation that improves vaccine uptake, coverage, compliance and readiness and is part of the innovative DRIVe safety technology portfolio. DRIVe researches and funds innovative solutions that are extremely daring, radical and disruptive, capable of transforming health security. Relevant projects in this portfolio can create new technologies or exploit existing technologies in innovative and disruptive ways.
As part of this program, Enesi will leverage its ImplaVax® platform, combining a flu-protective vaccine and its simple, robust, needle-free administration system, improving efficiency. vaccine, its thermal stability and its rapid administration to a target population. ImplaVax® could become a potentially disruptive technology not only for pandemic influenza, but also for many vaccines, vaccination protocols, infectious diseases and biological threats.
David Hipkiss, CEO of Enesi, commented:
"We are extremely proud to have been selected by BARDA DRIVe for this partnership.The DRIVe team has incredibly supported Enesi and has clearly recognized the need to revolutionize vaccine distribution as part of its mission to make Advancing research and development of medical countermeasures threatens health security.This is the latest in a series of key strategic partnerships and represents the next step in our journey to make a tangible difference. in the global health sector. "
This DRIVe project will include an badytical and preclinical evaluation of new ImplaVax® Solid Implant solid implants implant formulations of influenza vaccines marketed in validated models. In vitro testing will include confirmation of title generation, strength, and implant safety. In vivo tests will evaluate comparative efficacy and dosing regimens. The performance of solid dose implants versus placebo and active control administered at the needle and syringe will also be measured. The overall goal is to generate compelling evidence for the use of solid dose presentations as the preferred immunization method for a future pandemic influenza event.
About BARDA DRIVe
BARDA (Advanced Biomedical Research and Development Authority) is a key component of the Office of the Assistant Secretary for Preparedness and Response (ASPR) of the US Department of Health and Human Services. DRIVe (Division of Research, Innovation and Enterprise) is a BARDA initiative that supports the development of innovative products and approaches aimed at solving major health safety problems through products and technologies. innovative approaches.
DRIVe was created in June 2018 transforming health safety innovation to protect Americans from 21st century health threats. DRIVe's user-friendly EZ-BAA application process simplifies the way government builds partnerships with the industry. www.phe.gov/about/barda/
About Enesi Pharma
Enesi Pharma is an innovative pharmaceutical company that develops new products that can transform the performance and distribution of vaccines and have a significant impact on healthcare worldwide.
The company's main goal is to develop new solid-dose vaccines to combat a range of infectious and other selected diseases, in partnership with global companies, government agencies and non-governmental organizations.
Enesi's ImplaVax® formulation and device technologies offer significant potential benefits to patients, healthcare providers, healthcare professionals and payers through efficiency, safety, ease of use, reliability and ease of use. increased stability.
The company has established multiple collaborations to evaluate the possibilities of ImplaVax®-activated vaccines for a range of infectious and allergy-related diseases, including with BARDA DRIVe, the University of Oxford, Walter Reed Army Research Institute, Public Health England, Sementis and GeoVax.
Enesi's experienced management team has a proven track record of successfully developing and marketing innovative products that deliver valuable results for all stakeholders. For more information, visit www.enesipharma.com or follow Enesi on Twitter at the address www.twitter.com/enesi_pharma.
SOURCE Enesi Pharma
[ad_2]
Source link
